Literature DB >> 23188545

What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?

Hadrien Tranchart1, Jérémie H Lefèvre, Magali Svrcek, Jean-François Flejou, Emmanuel Tiret, Yann Parc.   

Abstract

BACKGROUND: In locally advanced rectal cancer (LARC) patients, major response to neoadjuvant radiotherapy (NR) has been associated with favorable long-term outcomes. Positive pathologic nodal status was recently proven to be associated with poor prognosis even after total regression of primary tumor (ypT0). The aim of this study was to evaluate the rate of lymph node (LN) involvement in patients with complete (ypT0) or major (TRG1: very few viable tumor cells) response.
METHODS: Included were patients with complete or major response after radiotherapy followed by surgery and histological examination of the whole specimen.
RESULTS: From 1996 to 2010, 245 patients with LARC were treated by NR. We collected clinical data for 53 patients (21.6 %) with ypT0 (n = 26, 49 %) or TRG1 (n = 27, 51 %) response. Sphincter-preserving surgery was performed in 40 patients (75 %). Overall, nine patients (16.9 %) presented LN involvement: 2 (7.7 %) in the ypT0 group and 7 (25.9 %) in the TRG1 group (NS). Patients with ypT3 tumors had significantly more invaded LN than patients with ypT1-T2 tumors (6 of 13 [46 %] vs 1 of 14 [7 %], p = .032). After median follow-up of 30 months (range, 1-160 months), 5-year disease-free and overall survivals were 88.2 and 89.0 %, respectively.
CONCLUSIONS: There was a clear cutoff between patients with ypT0-T2 (3 of 40, 7.5 %) and ypT3 (6 of 13, 46 %) concerning the incidence of metastatic LN in patients achieving pathologic complete or major response after NR. In patients with good clinical response, local full-thickness resection of the residual tumor could be a first step, followed by standard rectal resection in cases of ypT3.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23188545     DOI: 10.1245/s10434-012-2773-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Multiparametric MRI-based Radiomics approaches on predicting response to neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer.

Authors:  Yuan Cheng; Yahong Luo; Yue Hu; Zhaohe Zhang; Xingling Wang; Qing Yu; Guanyu Liu; Enuo Cui; Tao Yu; Xiran Jiang
Journal:  Abdom Radiol (NY)       Date:  2021-07-24

2.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Authors:  Natally Horvat; Harini Veeraraghavan; Monika Khan; Ivana Blazic; Junting Zheng; Marinela Capanu; Evis Sala; Julio Garcia-Aguilar; Marc J Gollub; Iva Petkovska
Journal:  Radiology       Date:  2018-03-07       Impact factor: 11.105

Review 3.  Management of oligometastatic rectal cancer: is liver first?

Authors:  Timur Mitin; C Kristian Enestvedt; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2015-04

4.  Prognostic Impact of the Neoadjuvant Rectal Score as Compared With the Tumor Regression Grade and Yield Pathologic TNM Stage in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy.

Authors:  Jin Ho Baek; Dong Won Baek; Byung Woog Kang; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Jong Gwang Kim
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

5.  Pathologic Complete Response Despite Nodal Yield Has Best Survival in Locally Advanced Rectal Cancer.

Authors:  Sumana Narayanan; Kristopher Attwood; Emmanuel Gabriel; Steven Nurkin
Journal:  J Surg Res       Date:  2020-03-12       Impact factor: 2.192

6.  Can tumor regression grade influence survival outcome in ypT3 rectal cancer?

Authors:  L Shen; L Wang; G Li; H Zhang; L Liang; M Fan; Y Wu; W Deng; W Sheng; J Zhu; Z Zhang
Journal:  Clin Transl Oncol       Date:  2015-11-02       Impact factor: 3.405

7.  A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design.

Authors:  Jérémie H Lefevre; Alexandra Rousseau; Magali Svrcek; Yann Parc; Tabassome Simon; Emmanuel Tiret
Journal:  BMC Cancer       Date:  2013-09-12       Impact factor: 4.430

8.  Is the pathological regression level of metastatic lymph nodes associated with oncologic outcomes following preoperative chemoradiotherapy in rectal cancer?

Authors:  Jung Pil Choi; Sung Joo Kim; In Ja Park; Seung Mo Hong; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Seok-Byung Lim; Jung Bok Lee; Chang Sik Yu; Jin Cheon Kim
Journal:  Oncotarget       Date:  2017-02-07

9.  Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.

Authors:  Claudio Belluco; Marco Forlin; Matteo Olivieri; Renato Cannizzaro; Vincenzo Canzonieri; Angela Buonadonna; Ettore Bidoli; Fabio Matrone; Giulio Bertola; Antonino De Paoli
Journal:  Ann Surg Oncol       Date:  2016-08-03       Impact factor: 5.344

10.  Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.

Authors:  Sung Min Jung; Chang Sik Yu; In Ja Park; Tae Won Kim; Jong Hoon Kim; Yong Sik Yoon; Seok-Byung Lim; Jin Cheon Kim
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.